Thrombopoietin
Also known as: Megakaryocyte growth and development factor, MGDF, MPL ligand, PEG-rHuMGDF, rhTPO, Thrombopoietin (protein), Tpiao, TPO
Source Thrombopoietin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Thrombopoietin (TPO) is a naturally occurring cytokine that drives the growth and maturation of megakaryocytes, the bone‑marrow cells that produce platelets. In research settings it is being explored as a tool to counteract chemotherapy‑induced thrombocytopenia (CIT) and to illuminate the biology of myeloproliferative neoplasms that involve the TPO receptor (TPOR). It is not an approved therapeutic agent.
Mechanism of Action
TPO binds to the TPOR (also called c‑Mpl) on hematopoietic stem and progenitor cells, triggering receptor dimerisation and activation of the JAK2‑STAT, MAPK and PI3K‑AKT pathways. These signals promote proliferation and differentiation of megakaryocyte precursors, increase platelet production, and support stem‑cell self‑renewal. Mutations in the MPL gene can cause constitutive TPOR activation, leading to excess platelet formation in certain myeloproliferative disorders.
What the Research Shows
Recent reviews describe persistent chemotherapy‑induced thrombocytopenia as a clinical problem that can be mitigated with thrombopoietin‑receptor agonists (TPO‑RAs) such as romiplostim, avatrombopag and eltrombopag, often administered in clinical trials or off‑label. A 2024 review notes that no FDA or EMA‑approved agents exist for CIT, but a growing body of evidence supports TPO‑RA use. A 2025 meta‑analysis of seven studies (348 patients) reported a pooled platelet increase of roughly 70 × 10⁹/L after TPO‑RA therapy. Another 2021 chapter outlines how MPL mutations drive TPOR signalling in myeloproliferative neoplasms, highlighting TPO pathway relevance to disease mechanisms and potential therapeutic targeting.
Reported Benefits
Evidence from the meta‑analysis and narrative reviews suggests that TPO‑RAs can raise platelet counts in patients with CIT, potentially reducing bleeding risk and allowing continuation of chemotherapy schedules. The reported mean increase of about 70 × 10⁹/L indicates a clinically meaningful effect. In addition, understanding TPO‑TPOR signalling aids the study of myeloproliferative neoplasms, where abnormal TPOR activation contributes to disease pathology.
Limitations of the Evidence
No TPO‑RA is currently approved specifically for CIT in the United States or Europe, limiting routine clinical use. The meta‑analysis pooled a modest number of trials with heterogeneous agents and dosing regimens, so generalisability is uncertain. Long‑term safety data are sparse, and most reports focus on short‑term platelet responses. Direct studies of native recombinant TPO in humans are not presented in the cited literature, leaving a gap in knowledge about its standalone therapeutic profile.
Safety Considerations
The reviews characterise TPO‑RA use in CIT as having "minimal apparent risks," but they also acknowledge that safety data are limited and derived mainly from trial settings. Potential concerns such as thrombotic events or marrow fibrosis, commonly discussed for TPO‑RAs, are not detailed in the abstracts, underscoring the need for careful monitoring and further safety evaluation before broader adoption.
How It Is Administered
Research formulations of thrombopoietin and its receptor agonists are delivered by injection, most commonly subcutaneous or intravenous routes. Recombinant human TPO, PEG‑ylated variants, and synthetic agonists are all administered as sterile solutions injected into the skin or vein, depending on the specific product and study protocol.
Routes of Administration
Goals & Uses
- Aplastic anemia supportHematologyLow
- Aplastic anemia / bone marrow failureHematologyLow
- Platelet production stimulation prior to stem cell transplantHematology / TransplantationModerate
- Chemotherapy‑induced thrombocytopeniaHematologyModerate
- Immune thrombocytopenia (ITP)HematologyModerate
- Chemotherapy-induced thrombocytopenia treatmentHematologyModerate
Contraindications
- Thrombotic disorders / hypercoagulable statesHematologicHigh
- Active thromboembolic diseaseVascularHigh
- History of TPO antibody-mediated thrombocytopeniaImmunologicHigh
- Known hypersensitivity to recombinant TPOImmunologicModerate
- Myeloproliferative neoplasmsOncologicHigh
Adverse Effects
- Bone painMusculoskeletalUncommon
- Fever and flu-like symptomsConstitutionalUncommon
- Injection site reactionsLocalCommon
- HeadacheNeurologicCommonPain in the head or upper neck
- Bone marrow fibrosisHematologicUncommon
- Thrombocytosis / thrombosisHematologicUncommon
- Neutralizing anti-TPO antibodies causing thrombocytopeniaImmunologicUncommon
- ThrombosisHematologicCommonFormation of a blood clot
Drug Interactions
- Romiplostim or EltrombopagHigh
- Other hematopoietic growth factors (e.g., G-CSF, EPO)Low
- TPO-receptor agonists (romiplostim, eltrombopag)Moderate
- Anticoagulants (e.g., warfarin, DOACs)Moderate
- Anticoagulants (e.g., warfarin, heparin)Moderate
Population Constraints
- PregnancyReproductive SafetyRelative
- Patients with active malignancyOncologyRelative
- Pediatric patientsAgeRelative
- Renal or hepatic impairmentOrgan DysfunctionRelative
Regulatory Status
- European UnionUnapprovedNo marketing authorization in the European Union
- United StatesUnapprovedInvestigational; not FDA‑approved
- United KingdomUnapprovedNot licensed for clinical use
Full-length recombinant human TPO (rhTPO, e.g., Tpiao) is approved in China for chemotherapy-induced thrombocytopenia. PEG-rHuMGDF (a truncated pegylated form) was withdrawn globally after causing neutralizing antibodies and thrombocytopenia in healthy volunteers. Not approved by FDA or EMA as a standalone agent.
Evidence & Sources
- Journal ArticleModerateSong AB, Al-Samkari H2025-01-01T00:00:00.000000Z
- Journal ArticleModerateAl-Samkari H2024-01-01T00:00:00.000000Z
- Journal ArticleModerateGuglielmelli P, Calabresi L2021-01-01T00:00:00.000000Z
- Journal ArticleHighGurumurthy G, et al.2025-01-01T00:00:00.000000Z
Frequently Asked Questions
What clinical situation is thrombopoietin research most focused on?
Current research concentrates on using thrombopoietin‑receptor agonists to treat chemotherapy‑induced thrombocytopenia, a condition that can delay or reduce cancer treatment because of low platelet counts.
Are there any approved drugs that act like thrombopoietin?
No. As of the cited literature, neither the U.S. FDA nor the European EMA have approved any thrombopoietin‑receptor agonist specifically for chemotherapy‑induced thrombocytopenia.
How does thrombopoietin affect blood cell production?
Thrombopoietin binds the TPOR on hematopoietic stem and progenitor cells, activating JAK2‑STAT, MAPK and PI3K pathways, which drive megakaryocyte proliferation and maturation, ultimately increasing platelet formation.
What are the main safety concerns with using TPO‑receptor agonists?
The cited reviews describe only minimal apparent risks, but they note that safety data are limited. Potential concerns such as excessive clot formation or marrow changes require monitoring in clinical studies.
How are thrombopoietin‑based agents administered in research?
They are given as injectable solutions, either intravenously or subcutaneously, using recombinant proteins or synthetic agonists formulated for sterile injection.
What is Thrombopoietin?
Thrombopoietin (TPO) is a naturally occurring cytokine that drives the growth and maturation of megakaryocytes, the bone‑marrow cells that produce platelets. In research settings it is being explored as a tool to counteract chemotherapy‑induced thrombocytopenia (CIT) and to illuminate the biology of myeloproliferative neoplasms that involve the TPO receptor (TPOR). It is not an approved therapeutic agent.
What is Thrombopoietin used for?
Thrombopoietin is educationally associated with: Aplastic anemia support, Aplastic anemia / bone marrow failure, Platelet production stimulation prior to stem cell transplant, Chemotherapy‑induced thrombocytopenia, Immune thrombocytopenia (ITP), Chemotherapy-induced thrombocytopenia treatment. Educational only — not medical advice.
How is Thrombopoietin administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Thrombopoietin?
Reported adverse effects include: Bone pain, Fever and flu-like symptoms, Injection site reactions, Headache, Bone marrow fibrosis, Thrombocytosis / thrombosis, Neutralizing anti-TPO antibodies causing thrombocytopenia, Thrombosis. This list is not exhaustive — consult a qualified clinician.
Who should avoid Thrombopoietin?
Recorded contraindications: Thrombotic disorders / hypercoagulable states, Active thromboembolic disease, History of TPO antibody-mediated thrombocytopenia, Known hypersensitivity to recombinant TPO, Myeloproliferative neoplasms. Consult a qualified clinician before use.